Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A2BO
|
|||
| Former ID |
DIB003121
|
|||
| Drug Name |
S-110
|
|||
| Synonyms |
DNA demethylating agent (myelodysplastic syndrome), Supergen
Click to Show/Hide
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 3 | [1], [2] | |
| Chronic myelogenous leukaemia [ICD-11: 2A20.0; ICD-10: C92.7; ICD-9: 205.1] | Phase 3 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [2] | ||
| Company |
SuperGen Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA [cytosine-5]-methyltransferase (DNMT) | Target Info | Inhibitor | [3] |
| DNA [cytosine-5]-methyltransferase 1 (DNMT1) | Target Info | Inhibitor | [4] | |
| KEGG Pathway | Cysteine and methionine metabolism | |||
| Metabolic pathways | ||||
| MicroRNAs in cancer | ||||
| Pathwhiz Pathway | Methionine Metabolism | |||
| Pathway Interaction Database | Regulation of retinoblastoma protein | |||
| Reactome | PRC2 methylates histones and DNA | |||
| NoRC negatively regulates rRNA expression | ||||
| DNA methylation | ||||
| WikiPathways | Trans-sulfuration and one carbon metabolism | |||
| Retinoblastoma (RB) in Cancer | ||||
| One Carbon Metabolism | ||||
| Trans-sulfuration pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02348489) SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.